Study Overview
Lead Institution:
A hospital in China · Department of Oncology
Study Type
Prospective · Single-arm · Open-label
Class III therapeutic medical device registration clinical trial (China)
Study Population
Patients with imaging-visible, needle-accessible solid tumors
Total number of tumors ≤ 10
ECOG performance status ≤ 2
%20.webp)
Primary Endpoint
Imaging-confirmed complete response (CR) rate assessed at 30–45 days after treatment,
with a target CR rate of ≥95%.
Secondary Endpoints
• ≥ 30% reduction in tumor volume within 1 hour after injection (ultrasound); • Improvement in cancer-related pain, heart rate, and quality-of-life indicators; • Reduction in inflammatory markers on routine blood tests
Treatment Method
Intratumoral injection of 2% chlorine dioxide working solution
Ultrasound- or CT-guided
Once every 7 days, for a total of 4 treatments
Intravenous sedation only; no general anesthesia required
Procedure comparable to image-guided tumor biopsy
